Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132

Posted: Thursday, December 7, 2017

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses the efficacy of sacituzumab govitecan (IMMU-132), an anti–Trop-2-SN-38 antibody-drug conjugate, as ≥ 3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer.